Phibro reports record fiscal 2026 sales, plans Chicago Heights plant closure, issues FY27 guidance

Phibro Animal Health Corporation announced on August 26, 2026 that it will close its Chicago Heights manufacturing facility, a site added through the MFA acquisition in 2024. The company said through the MFA acquisition in 2024, Phibro added several manufacturing facilities, and since then has conducted a comprehensive review of its manufacturing network to align production footprint with current business needs and future operational requirements.¹ As a result, Phibro decided to close the Chicago Heights facility as part of a strategic consolidation of its manufacturing network, with production expected to cease during the summer of 2027, affecting approximately 100 employees; manufacturing currently done there will move to other Phibro-owned facilities and select third-party contract manufacturers.¹

The closure was announced alongside fourth quarter and full fiscal year 2026 results. For the quarter ended June 30, 2026, net sales were $396.7 million, up $18.1 million or 5%, with net income of $21.7 million, up 26%, and adjusted EBITDA of $64.2 million, up 29%.¹ For the full fiscal year, net sales reached $1,518.1 million, up $221.9 million or 17%, net income was $99.7 million, up $51.5 million, and adjusted EBITDA rose 39% to $255.0 million.¹

For fiscal 2027, Phibro guided to net sales of $1.55 billion to $1.60 billion, adjusted EBITDA of $258 million to $268 million, and adjusted net income of $140 million to $147 million.¹ The company noted its outlook incorporates uncertainty tied to virginiamycin's regulatory status in Brazil, saying guidance assumes only minimal virginiamycin sales in Brazil for fiscal 2027 because the required therapeutic indications have not yet been obtained.¹ Phibro also said GAAP guidance excludes non-cash and other one-time charges that may result from the Chicago Heights closure, and assumes no foreign exchange gains or losses for fiscal 2027.¹

On cash position, Phibro reported free cash flow of $9.9 million for the twelve months ended June 30, 2026, a 2.9x gross leverage ratio with $737.9 million in total debt, and cash and short-term investments of $82.0 million as of June 30, 2026.¹